Oncolytic Virus Immunotherapy

• Autore: Marchini Antonio
• Pubblicazione: Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
• Descrizione fisica: 1 online resource (366 p.)
• Soggetto topico: Clinical and internal medicine; Medicine and Nursing
• Soggetto non controllato: adenovirus; adoptive T cell therapy; antigen-agnostic vaccination; antitumor immune response; arming; biomarkers; cancer; cancer immune therapy; cancer immunotherapy; cancer therapy; CAR T cell; checkpoint inhibitor; checkpoint inhibitors; class I HLA; clinical trials; colorectal cancer; combination therapy; combinatory therapy; CTLA-4; delivery; DNA methyltransferase inhibitor (DNMTi); epigenetic silencing; genetic modification; glioblastoma; HER2; herpes simplex virus; HSV-1; immune checkpoint blockade; immune checkpoint inhibitor; immunoediting; immunogenic cell death; immunostimulatory; immunosurveillance; immunotherapy; measles virus; melanoma; multi-stage; n/a; NDV; newcastle disease virus; oncogenic signaling; oncolytic; oncolytic adenovirus; oncolytic virus; oncolytic viruses; pancreatic cancer; pancreatic ductal adenocarcinoma; parvovirus; PD-1; PD-L1; personalized oncolyticvirotherapy; RAS; reovirus; retargeted virus; small molecule; targeting; tropism retargeting; tumor; tumor microenvironment; type I interferon; vaccination; vector engineering; vesicular stomatitis virus; viral mimicry; virotherapy; αvβ6 integrin
• Persona (resp. second.): IlkowCarolina S; MelcherAlan; MarchiniAntonio
• Sommario/riassunto: Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
• Titolo autorizzato: Oncolytic Virus Immunotherapy
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910566462203321
• Lo trovi qui: Univ. Federico II